Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: bob who wrote (62)	12/13/1998 8:46:00 PM
From: Epicenter	Read Replies (2) \| Respond to of 566

Bob: I've been doing science for over 20 years and as far as I know, I know of only one reagent (drugs) that is really tumor-specific. For everything else, efficacy and toxicity is a matter of quantitative difference and not a basic qualitative difference. Also, not seeing effects on normal cells in tissue culture has very little relevance to actual in vivo results, particularly in humans AND IN CHRONIC STUDIES. (Of course, it's better than no difference in tissue culture cells). The biology is not that simple. For example, what is the definition of "normal" cells. If it isn't toxic to some skin cells in tissue culture, what about against the thousands of different kinds of cells in our body? Only, long term in vivo studies will show. At the least, 13 week toxicity study in 2 kinds of animals and then longer studies later. As I have written before, I hope it works but my scientific bend makes me a little skeptical (That's why I don't like to discover and develop drugs that are for extremely long-term chronic use, given a choice. I would choose a short-term drug any day over a long term drug although market potential is generally smaller). I don't mean to be negative but more cautious. I hope it's helpful. Epicenter